Orthofix Medical (OFIX) Stifel 2024 Healthcare Conference summary

Conference overview

• Leadership highlighted a transformation story, emphasizing underappreciated growth and profitability, supported by a discounted valuation.

• New management team, with over 250 years of combined MedTech experience, has driven improvements in every business metric since joining less than a year ago.

• Focus areas include disciplined execution, capital allocation, and driving free cash flow, with long-range targets set through 2027.

• The organization is investing in value creation while actively taking market share, not just building for the future.

• The leadership team is confident in the platform's ability to deliver above-market growth across all business segments.

Strategic initiatives and operational focus

• Emphasis on profitable growth, with education and accountability measures implemented across the organization.

• Gross margin improvement is a key contributor to mid-teens EBITDA targets, with operational focus on insourcing and optimizing distribution.

• Strategic partnerships with larger, exclusive distributors are improving resource utilization and inventory efficiency.

• The enabling technology platform, 7D, is a differentiator, reducing OR setup time and increasing account stickiness.

• Earnout-based placements of enabling technology are ahead of schedule, driving tangible revenue growth.

Business segment performance and growth drivers

• Spine fixation business is growing at 18%, three times the market rate, with strong performance in bone growth therapy and biologics.

• Bone growth therapy holds over 50% market share and continues to grow, while the fracture market entry has quickly made the company the number two player.

• Investments are shifting toward the deformity space in spine, where higher ASPs and differentiation are possible.

• The hardware portfolio now supports 90% of spine cases, enabling deeper account penetration and higher revenue per procedure.

• Cross-functional selling across spine, biologics, bone growth therapy, and enabling technology is driving multi-product adoption in accounts.